ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "A Pragmatic Approach to Psychedelic Drug Development"
Episode Synopsis
In this episode, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development.
Key topics include:
The evolution of atai Life Sciences, from a fund to a biotech company.
Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter.
Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
Tackling clinical trial challenges, including the placebo effect and trial design complexities.
Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.
Key topics include:
The evolution of atai Life Sciences, from a fund to a biotech company.
Innovative drug delivery approaches, like DMT oral thin films, and why simplicity and scalability matter.
Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
Tackling clinical trial challenges, including the placebo effect and trial design complexities.
Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.
More episodes of the podcast Power to the Patients
Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan
21/10/2025
Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine
15/10/2025
In God we trust